Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19323694 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | September 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19182966 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19182985 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19182977 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | April 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 18973646 | MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF | December 2024 | October 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18431262 | COMBINATION THERAPY FOR TREATING CANCER | February 2024 | May 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18511036 | METHODS FOR TREATING CANCER | November 2023 | September 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18372495 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | September 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18372398 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | September 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18338355 | SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND PREPARATION METHOD THEREFOR | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18036719 | PROPHYLAXIS AND TREATMENT OF ANGIOEDEMA | May 2023 | January 2026 | Allow | 33 | 1 | 0 | Yes | No |
| 18029579 | Crystal of Thyroid Hormone B Receptor Agonist, Process for Preparing The Same and Use Thereof | March 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18028120 | SALT OF ARYLAMINOQUINAZOLINE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | March 2023 | January 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18027759 | CSF1R KINASE INHIBITOR AND USE THEREOF | March 2023 | February 2026 | Allow | 35 | 1 | 1 | Yes | No |
| 18185268 | TREATMENT OF LOW-GRADE GLIOMA WITH MIRDAMETINIB | March 2023 | January 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18177073 | 18-MC SALT FORMS | March 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18023797 | Methods of Managing Cocaine or Other Drug Addictions | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18021654 | METHODS FOR TREATING HYPERCHOLESTEROLEMIA | February 2023 | July 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18040102 | NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF | January 2023 | March 2026 | Allow | 37 | 2 | 0 | Yes | No |
| 18018587 | USE OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING BREAST CANCER | January 2023 | February 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 18007020 | PREPARATION METHOD OF SALFAPRODIL FREEZE-DRIED POWDER INJECTION, AND PRODUCT AND USE THEREOF | January 2023 | November 2025 | Allow | 34 | 1 | 0 | No | No |
| 18004731 | OXOPYRROLIDINE FPR2 AGONISTS | January 2023 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18014971 | Combination Therapy for Cancer | January 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18071153 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | November 2022 | November 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 18057738 | Pyrazolo Compounds and Methods of Use Thereof | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 18056877 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | November 2022 | September 2024 | Abandon | 22 | 2 | 0 | No | No |
| 18056717 | SALT AND SOLID FORMS OF TABERNANTHALOG | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17983971 | Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators | November 2022 | May 2024 | Allow | 18 | 2 | 1 | No | No |
| 17970938 | Phytol-based surfactants and methods therefor | October 2022 | June 2024 | Allow | 20 | 2 | 0 | No | No |
| 17918249 | VACCINE ADJUVANTS | October 2022 | November 2025 | Allow | 37 | 1 | 0 | No | No |
| 18045210 | RADIATION-ACTIVATABLE PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USE | October 2022 | June 2024 | Allow | 20 | 2 | 0 | No | No |
| 17955543 | TOPICAL ANTIMICROBIAL FORMULATIONS | September 2022 | September 2025 | Abandon | 36 | 3 | 0 | Yes | No |
| 17934769 | NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17906996 | CRYSTAL FORM OF NITROXOLINE PRODRUG, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | September 2022 | November 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17910654 | CRYSTAL OF A HYPOXANTHINE COMPOUND | September 2022 | March 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17940984 | PREPARATION METHOD OF TOFACITINIB CITRATE | September 2022 | September 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17902795 | USES OF CORYLIN AND/OR NEOBAVAISOFLAVONE IN TREATING SYMPTOMS ASSOCIATED WITH SENESCENCE | September 2022 | December 2024 | Abandon | 27 | 4 | 0 | No | No |
| 17802203 | Processes for the Preparation of Multicomponent Crystalline Forms of Active Pharmaceutical Ingredients Using Solvent Vapour | August 2022 | October 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17892651 | COMBINATION THERAPY FOR TREATING CANCER | August 2022 | May 2024 | Abandon | 20 | 1 | 1 | No | No |
| 17799508 | INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE, COMPOSITIONS AND USES THEREOF | August 2022 | August 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17793406 | CRYSTALLINE FORM OF FLUVATINIB OR FLUVATINIB METHANESULFONATE AND PREPARATION METHOD THEREFOR | July 2022 | December 2025 | Allow | 41 | 2 | 0 | No | No |
| 17866008 | METHODS OF USING SUBSTITUTED FLAVONES FOR TREATING BONE DISORDERS | July 2022 | March 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17793275 | CRYSTAL FORM OF POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR | July 2022 | June 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17860599 | Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell Lymphoma | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17857970 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERTENSION | July 2022 | April 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17855823 | PREPARATION AND APPLICATION OF TRITERPENOIDS WITH EFFECT OF IMPROVING GLUCOSE AND LIPID METABOLISM DISORDERS | July 2022 | March 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17854685 | MULTI-FUNCTIONAL NANOPARTICLE TARGETED TO BREAST CANCER, PREPARATION METHOD AND USE THEREOF | June 2022 | May 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17789095 | METHOD FOR PREPARING ISAVUCONAZONIUM SULFATE | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17787870 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | June 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17787113 | PRMT5 INHIBITORS | June 2022 | September 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17838171 | DUAL TREATMENT OF MIGRAINE | June 2022 | July 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17756277 | CRYSTAL FORMS OF FUSED RING COMPOUND, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | May 2022 | August 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17777154 | COMPOUND AS HIGHLY SELECTIVE ROS1 INHIBITOR AND USE THEREOF | May 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17775795 | NOVEL SALT OF TERPHENYL COMPOUND | May 2022 | May 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17733419 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | April 2022 | May 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17732124 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | April 2022 | April 2025 | Allow | 36 | 2 | 1 | No | No |
| 17730764 | METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE | April 2022 | June 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17703891 | PREPARATION OF GHRELIN O-ACYLTRANSFERASE INHIBITORS | March 2022 | February 2025 | Allow | 35 | 0 | 0 | No | No |
| 17700063 | COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE | March 2022 | November 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17639015 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | February 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17631833 | INTRAVENOUS VITAMIN C THERAPY PROTOCOL FOR THE TREATMENT OF CANCER | January 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17627946 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF | January 2022 | May 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17576208 | TREATMENT OF CHRONIC COUGH, BREATHLESSNESS AND DYSPNEA | January 2022 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17618557 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | December 2021 | August 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17547940 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | December 2021 | October 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17617011 | METHOD FOR TREATMENT OF AT RISK PATIENTS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17542540 | NOVEL ESTERS OF MEDROXYPROGESTERONE | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17596227 | POLYMORPH OF CDK9 INHIBITOR AND PREPARATION METHOD FOR POLYMORPH AND USE THEREOF | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17615369 | COMPOSITION FOR CASPASE INHIBITOR PRODRUG INJECTION | November 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17614114 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | November 2021 | September 2025 | Allow | 46 | 2 | 1 | No | No |
| 17610368 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | November 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17607733 | PRODRUG OF CASPASE INHIBITOR | October 2021 | November 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17606998 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | October 2021 | February 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17509238 | SYSTEMS AND METHODS FOR TREATMENTS OF AN EYE WITH A PHOTOSENSITIZER | October 2021 | September 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17510050 | Treating Y537S Mutant Breast Cancer with RAD1901 and mTOR inhibitor | October 2021 | August 2023 | Allow | 22 | 2 | 0 | Yes | No |
| 17504243 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | October 2021 | September 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17593965 | CROSSLINKED SILK FIBROIN-BASED COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | September 2021 | October 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17599847 | PRODUCTION METHOD FOR RARE FATTY ACID USING NOVEL ENZYME, AND NOVEL RARE FATTY ACID | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17599338 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | September 2021 | March 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17598611 | SYNTHESIS AND APPLICATION OF DILTIAZEM HYDROCHLORIDE | September 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17598389 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | September 2021 | March 2026 | Abandon | 54 | 4 | 0 | Yes | No |
| 17439630 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA | September 2021 | December 2024 | Allow | 39 | 1 | 0 | No | No |
| 17438753 | CRYSTAL FORM E OF BULLEYACONITINE A, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | September 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17438024 | METHODS AND COMPOSITIONS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDER | September 2021 | July 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17437030 | 1-PYRIDYL-PYRAZOLYL AMIDE COMPOUNDS AND PREPARATION AND USES THEREOF | September 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17412851 | DIETARY SUPPLEMENT FORMULATED BASED ON ALL-TRANS FORM OF MENAQUINONE-7 | August 2021 | April 2024 | Abandon | 32 | 3 | 1 | No | No |
| 17428867 | Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection | August 2021 | September 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17425810 | MEDICAMENT FOR PROPHYLAXIS OR TREATMENT OF PULMONARY FIBROSIS | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17423819 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | July 2021 | February 2026 | Abandon | 55 | 4 | 0 | No | No |
| 17423745 | CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYL SULFONYL) BENZAMIDE COMPOUNDS OR ITS SALTS OR SOLVATES | July 2021 | March 2025 | Allow | 44 | 2 | 0 | No | No |
| 17416711 | CYCLIN-DEPENDENT KINASE INHIBITORS | June 2021 | May 2025 | Abandon | 47 | 3 | 0 | No | No |
| 17414278 | L-TRIIODOTHYRONINE (T3) FOR USE IN LIMITING MICROVASCULAR OBSTRUCTION | June 2021 | December 2025 | Allow | 54 | 3 | 0 | Yes | Yes |
| 17413327 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17413185 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17309487 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN MANUFACTURE OF MEDICAMENT FOR TREATING CANCER | June 2021 | November 2025 | Abandon | 53 | 5 | 0 | No | No |
| 17295721 | AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMA | May 2021 | August 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17292863 | FORMULATIONS OF INFLUENZA THERAPEUTICS | May 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17313955 | EPINEPHRINE SPRAY FORMULATIONS | May 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17291273 | MONOBACTAM COMPOUNDS AND USE THEREFOR | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17289122 | METHOD OF TREATMENT OF P53 WT TUMORS | April 2021 | June 2024 | Allow | 38 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAHLIN, HEATHER RAQUEL.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DAHLIN, HEATHER RAQUEL works in Art Unit 1629 and has examined 73 patent applications in our dataset. With an allowance rate of 38.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner DAHLIN, HEATHER RAQUEL's allowance rate of 38.4% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DAHLIN, HEATHER RAQUEL receive 2.30 office actions before reaching final disposition. This places the examiner in the 65% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DAHLIN, HEATHER RAQUEL is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +49.7% benefit to allowance rate for applications examined by DAHLIN, HEATHER RAQUEL. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.9% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.8% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.